Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company's products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-608-3105100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Cellular Dynamics International (NASDAQ:ICEL) Frequently Asked Questions
What is Cellular Dynamics International's stock symbol?
Cellular Dynamics International trades on the NASDAQ under the ticker symbol "ICEL."
How were Cellular Dynamics International's earnings last quarter?
Cellular Dynamics International Inc (NASDAQ:ICEL) issued its quarterly earnings data on Thursday, March, 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.44) by $0.08. The company had revenue of $6.60 million for the quarter, compared to analysts' expectations of $5 million. View Cellular Dynamics International's Earnings History.
Has Cellular Dynamics International been receiving favorable news coverage?
News headlines about ICEL stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cellular Dynamics International earned a news impact score of 1.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Cellular Dynamics International?
Shares of ICEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellular Dynamics International's official website?
How can I contact Cellular Dynamics International?
Cellular Dynamics International's mailing address is 525 Science Dr, MADISON, WI 53711-1082, United States. The company can be reached via phone at +1-608-3105100.
MarketBeat Community Rating for Cellular Dynamics International (NASDAQ ICEL)
MarketBeat's community ratings are surveys of what our community members think about Cellular Dynamics International and other stocks. Vote "Outperform" if you believe ICEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
